Medicamen Biotech Limited (MEDICAMEQ) AI Stock Analysis

• Market Cap: ₹4.65B
• Dividend Yield: 0.26%
• Average Volume (3M): 2.40K
• Price to Earnings (P/E): 41.8
• Beta (1Y): 1.65
• Revenue Growth: -9.16%
• EPS Growth: 49.09%
• Country: IN
• Employees: 378
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 1.97
• Shares Outstanding: 13,562,815
• 10 Day Avg. Volume: 3,620
• 30 Day Avg. Volume: 2,395
• PEG Ratio: -2.50
• Price to Book (P/B): 2.95
• Price to Sales (P/S): 3.86
• P/FCF Ratio: -52.55
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 57 Neutral
• Price Target: ₹355.00 ▼(-3.24% Downside)

The score is primarily held back by weak cash flow (negative operating and free cash flow) and a high valuation (P/E 44.186 with a low dividend yield). These are partially offset by a stable balance sheet and relatively healthy operating margins, while technical signals remain mixed with negative MACD.

Positive Factors

Healthy operating margins

Sustained healthy EBIT/EBITDA margins indicate durable operational efficiency and pricing power in core formulations. This margin cushion supports reinvestment, absorbs demand shocks, and helps sustain profitability even if revenue fluctuates, improving medium‑term resilience.

Stable balance sheet and capital structure

A solid equity ratio and moderate leverage reduce refinancing and solvency risk, giving management flexibility to invest or withstand industry cycles. This structural balance supports credit access and long‑term solvency, strengthening the company’s ability to execute strategic plans.

Integrated finished-dosage business with export reach

Owning development, manufacturing and marketing for finished dosages across domestic and export markets provides diversified revenue channels and operational control. This integrated model supports repeat contract opportunities, scale benefits, and resilience from geographic diversification.

Negative Factors

Negative operating and free cash flow

Persistent negative operating and free cash flow erodes internal funding for capex, working capital and dividends. Over months this forces reliance on external financing or asset sales, increasing financial risk and constraining strategic investments and growth execution.

Weak cash conversion of reported earnings

A poor operating‑cash‑to‑net‑income ratio means reported profits don’t translate into cash, reducing real liquidity. Persisting this gap undermines the quality of earnings, hampers debt servicing and capex funding, and raises the risk profile for creditors and investors over the medium term.

Inconsistent revenue growth and margin volatility

Fluctuating revenues (recently negative year‑over‑year) and volatile net margins make cash flow and earnings forecasting difficult. This reduces predictability for reinvestment and operational planning, complicates long‑term strategy execution, and can weaken investor and partner confidence.

Medicamen Biotech Limited Business Overview & Revenue Model

Company Description

Medicamen Biotech Limited manufactures and sells pharmaceutical formulations in India. The company offers its products in various forms, including tablets, capsules, liquid and dry syrups, and ointments. It also provides oral rehydration solution, mouth wash, and dental care products. The company was incorporated in 1993 and is based in New Delhi, India.

How the Company Makes Money

Medicamen Biotech Limited generates revenue primarily through the sale of its pharmaceutical products, including generics and APIs, to healthcare providers, hospitals, and pharmacies. The company benefits from its extensive product portfolio, which allows it to capture diverse market segments. Key revenue streams include direct sales, contract manufacturing, and strategic partnerships with other pharmaceutical firms for co-development and distribution of products. Additionally, MEDICAMEQ may engage in licensing agreements for its proprietary technologies or formulations, further diversifying its income sources. The company's commitment to research and development enhances its competitive advantage, potentially leading to new product launches that can significantly boost revenue.

Medicamen Biotech Limited Financial Statement Overview

Summary

Mixed fundamentals: healthy EBIT/EBITDA margins and a solid balance sheet (moderate leverage, good equity position), but cash generation is weak with negative operating cash flow and free cash flow, and revenue growth has been inconsistent.

Income Statement

Medicamen Biotech Limited has shown a mixed performance in its income statement. The gross profit margin has been moderately strong, but net profit margin has seen some volatility. Revenue growth has been inconsistent, with significant fluctuations year over year. Notably, EBIT and EBITDA margins are relatively healthy, indicating efficient cost management despite variability in revenue.

Balance Sheet

The balance sheet of Medicamen Biotech Limited reflects a stable financial structure. The company maintains a reasonable debt-to-equity ratio, suggesting moderate leverage. The return on equity is satisfactory, reflecting effective use of equity capital. The equity ratio is solid, showing a strong equity position relative to total assets, which is favorable for long-term solvency.

Cash Flow

Medicamen Biotech Limited's cash flow statement reveals challenges, primarily with negative free cash flow over the past years, indicating potential liquidity issues. The operating cash flow to net income ratio is concerning, as operating cash flow has been negative, suggesting difficulties in converting net income into cash. This could pose risks to financial flexibility if it persists.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.63B	1.63B	1.79B	1.41B	1.15B	1.13B
Gross Profit	704.27M	389.90M	852.01M	687.74M	479.88M	335.16M
EBITDA	211.56M	201.02M	245.66M	277.12M	258.07M	204.25M
Net Income	89.48M	71.08M	109.31M	148.44M	148.98M	121.29M
Balance Sheet
Total Assets	0.00	2.97B	2.95B	2.79B	2.26B	1.94B
Cash, Cash Equivalents and Short-Term Investments	37.59M	37.59M	147.86M	207.79M	38.25M	38.91M
Total Debt	0.00	332.53M	311.12M	257.09M	257.96M	188.19M
Total Liabilities	-2.13B	841.04M	875.67M	851.03M	792.24M	611.18M
Stockholders Equity	2.13B	2.13B	2.07B	1.93B	1.46B	1.33B
Cash Flow
Free Cash Flow	0.00	-119.32M	-130.31M	-128.94M	-44.99M	-51.94M
Operating Cash Flow	0.00	-98.59M	-67.44M	-62.93M	41.09M	127.72M
Investing Cash Flow	0.00	-23.78M	-55.63M	-58.80M	-84.73M	-178.13M
Financing Cash Flow	0.00	12.16M	63.13M	291.27M	42.98M	58.39M

Medicamen Biotech Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 366.90
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:MEDICAMEQ, the sentiment is Negative. The current price of 366.9 is below the 20-day moving average (MA) of 369.83, below the 50-day MA of 381.70, and below the 200-day MA of 384.14, indicating a bearish trend. The MACD of -9.48 indicates Positive momentum. The RSI at 34.94 is Neutral, neither overbought nor oversold. The STOCH value of 13.84 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:MEDICAMEQ.

Medicamen Biotech Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VENUSREM	72 Outperform	₹10.94B	14.33	―	―	13.32%	218.38%
INDSWFTLAB	66 Neutral	₹9.25B	3.11	―	―	-37.70%	-19.79%
SAKAR	66 Neutral	₹8.58B	44.24	―	―	24.20%	55.01%
ZIMLAB	63 Neutral	₹3.48B	52.76	―	―	-5.82%	-59.22%
MEDICAMEQ	57 Neutral	₹4.65B	41.80	―	0.26%	-9.16%	49.09%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
NECLIFE	46 Neutral	₹3.01B	-0.85	―	―	-30.27%	-3470.06%